ReviewJournal of clinical microbiology2017
Establishment and Use of Epidemiological Cutoff Values for Molds and Yeasts by Use of the Clinical and Laboratory Standards Institute M57 Standard.
Review in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Article
- Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026Article
- Trichophyton indotineae: Rise, Diagnosis, Treatment, and Future Directions.American journal of clinical dermatology · 2026Review
- Establishment of epidemiological cutoff values for clinically relevantAntimicrobial agents and chemotherapy · 2026Article
- Transcriptomic and phenotypic responses of Corynespora cassiicola to the JNK inhibitor SP600125.Molecular biology reports · 2026Article
- Successful desensitization to liposomal amphotericin B for the treatment of disseminated cryptococcosis in pregnancy: a case report.ASM case reports · 2026Article
- Article
- Evaluation of the MIC test strips for antifungal susceptibility testing ofJournal of clinical microbiology · 2025Article
- Establishment of epidemiological cutoff values forJournal of clinical microbiology · 2025Article
- Antifungal susceptibility and multilocus sequence typing (MLST) of Cryptococcus neoformans complex from HIV-associated cryptococcal meningitis patients in Manaus, Amazonas, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Low utilization of epidemiological cutoff values to interpretJournal of clinical microbiology · 2024Article
- Fusarioid keratitis and other superficial infections: A 10-years prospective study from Northeastern Brazil.PLoS neglected tropical diseases · 2024Article
- Commercial Methods for Antifungal Susceptibility Testing of Saprophytic Molds: Can They Be Used to Detect Resistance?Journal of fungi (Basel, Switzerland) · 2024Review
- Article
- Uncovering a NovelJournal of fungi (Basel, Switzerland) · 2024Article
- Evaluation of the efficacy of novel topical antifungal agents against dermatophytes in North India: A prospective study.Current medical mycology · 2024Article
- Pore-forming peptide C14R exhibits potent antifungal activity against clinical isolates ofFrontiers in cellular and infection microbiology · 2024Article
- Post-transcriptional control of antifungal resistance in human fungal pathogens.Critical reviews in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Breakpoints are used to predict whether an antifungal agent will be clinically effective against a particular fungal isolate. They are based on a combination of MIC values, pharmacokinetic/pharmacodynamic values, and clinical outcome data. For many fungus-antifungal combinations, these data might never be available. For these combinations, epidemiological cutoff values (ECVs) provide a methodology for categorizing isolates as either wild type (WT) or non-WT. In this review, we define ECVs, explain how they are generated using the CLSI methodology in standard M57, and describe how they can be used in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.